A murine model of dry eye induced by topical administration of erlotinib eye drops

Yang,Qi‑Chen; Bao,Jing; Li,Cheng; Tan,Gang; Wu,An‑Hua; Ye,Lei; Ye,Lin‑Hong; Zhou,Qiong; Shao,Yi

doi:10.3892/ijmm.2017.3353

A murine model of dry eye induced by topical administration of erlotinib eye drops

Authors:
- Qi‑Chen Yang
- Jing Bao
- Cheng Li
- Gang Tan
- An‑Hua Wu
- Lei Ye
- Lin‑Hong Ye
- Qiong Zhou
- Yi Shao
View Affiliations

Affiliations: Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Xiamen, Fujian 361102, P.R. China, Department of Ophthalmology, The First Affiliated Hospital of the University of South China, Hengyan, Hunan 421001, P.R. China
Published online on: December 29, 2017 https://doi.org/10.3892/ijmm.2017.3353
Pages: 1427-1436
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the effects of erlotinib on mouse tear function and corneal epithelial tissue structure were investigated. Throughout the 3 weeks of treatment, no notable differences were observed in the body, eye or lacrimal gland weights of the control and experimental mice. However, in the experimental group, the tear volume and break‑up times of tear film were significantly lower following treatment with erlotinib compared with the control group. Corneal fluorescein staining in the experimental group revealed patchy staining, and the Lissamine green staining and inflammatory index were significantly higher in the experimental group at 3 weeks than in the control group. In the experimental group, the number of corneal epithelium layers increased significantly following treatment with erlotinib for 3 weeks and a significant increase in the number of vacuoles was observed compared with the control group. Treatment with erlotinib significantly increased the corneal epithelial cell apoptosis, and led to a significantly increased number of epithelial cell layers and increased keratin 10 expression. It also significantly reduced the number of conjunctival goblet cells. Transmission electron microscopy and scanning electron microscopy revealed that the corneal epithelial surface was irregular and there was a substantial reduction and partial loss of the microvilli in the experimental group. Mice treated with erlotinib also exhibited an increased protein expression of tumor necrosis factor‑α and decreased protein expression of phosphorylated‑epidermal growth factor receptor in the corneal epithelial cells. The topical application of erlotinib eye drops was revealed to induce dry eyes in mice. This is a novel method of developing a model of dry eyes in mice.

View Figures

View References

1	Gansler T, Ganz PA, Grant M, Greene FL, Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, et al: Sixty years of CA: A cancer journal for clinicians. CA Cancer J Clin. 60:345–350. 2010. View Article : Google Scholar : PubMed/NCBI
2	Vijayvergia N and Mehra R: Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 74:437–446. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
4	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
5	Verkhivker GM: Exploring sequence-structure relationships in the tyrosine kinome space: Functional classification of the binding specificity mechanisms for cancer therapeutics. Bioinformatics. 23:1919–1926. 2007. View Article : Google Scholar : PubMed/NCBI
6	Yin S, Zhou L, Lin J, Xue L and Zhang C: Design, synthesis and biological activities of novel oxazolo[4,5-g]quinazolin-2(1H)-one derivatives as EGFR inhibitors. Eur J Med Chem. 101:462–475. 2015. View Article : Google Scholar : PubMed/NCBI
7	Xiong X, Liu H, Fu L, Li L, Li J, Luo X and Mei C: Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines. Chemotherapy. 54:463–474. 2008. View Article : Google Scholar : PubMed/NCBI
8	Dickler MN, Cobleigh MA, Miller KD, Klein PM and Winer EP: Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 115:115–121. 2009. View Article : Google Scholar
9	Fraunfelder FT, Sciubba JJ and Mathers WD: The role of medications in causing dry eye. J Ophthalmol. 2012:2858512012. View Article : Google Scholar : PubMed/NCBI
10	Johnson KS, Levin F and Chu DS: Persistent corneal epithelial defect associated with erlotinib treatment. Cornea. 28:706–707. 2009. View Article : Google Scholar : PubMed/NCBI
11	Morishige N, Hatabe N, Morita Y, Yamada N, Kimura K and Sonoda KH: Spontaneous healing of corneal perforation after temporary discontinuation of erlotinib treatment. Case Rep Ophthalmol. 5:6–10. 2014. View Article : Google Scholar : PubMed/NCBI
12	Saint-Jean A, Sainz de la Maza M, Morral M, Morral M, Torras J, Quintana R, Molina JJ and Molina-Prat N: Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: Report of 5 cases. Ophthalmology. 119:1798–1802. 2012. View Article : Google Scholar : PubMed/NCBI
13	Barabino S, Chen W and Dana MR: Tear film and ocular surface tests in animal models of dry eye: Uses and limitations. Exp Eye Res. 79:613–621. 2004. View Article : Google Scholar : PubMed/NCBI
14	Romay C, Armesto J, Remirez D, González R, Ledon N and García I: Antioxidant and anti‑inflammatory properties of C‑phycocyanin from blue-green algae. Inflamm Res. 47:36–41. 1998. View Article : Google Scholar : PubMed/NCBI
15	Zhang Z, Yang WZ, Zhu ZZ, Hu QQ, Chen YF, He H, Chen YX and Liu ZG: Therapeutic effects of topical doxycycline in a benzalkonium chloride-induced mouse dry eye model. Invest Ophthalmol Vis Sci. 55:2963–2974. 2014. View Article : Google Scholar : PubMed/NCBI
16	Lemp MA: Report of the national eye institute/industry workshop on clinical trials in dry eyes. Clao J. 21:221–232. 1995.PubMed/NCBI
17	Williams KA, Standfield SD, Smith JR and Coster DJ: Corneal graft rejection occurs despite Fas ligand expression and apoptosis of infiltrating cells. Br J Ophthalmol. 89:632–638. 2005. View Article : Google Scholar : PubMed/NCBI
18	Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N and Sliwkowski MX: Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66:8163–8171. 2006. View Article : Google Scholar : PubMed/NCBI
19	Minna JD and Dowell J: Erlotinib hydrochloride. Nat Rev Drug Discov. (Suppl): S14–S15. 2005.PubMed/NCBI
20	The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 5:75–92. 2007. View Article : Google Scholar
21	Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, et al: TFOS DEWS II Epidemiology Report. Ocul Surf. 15:334–365. 2017. View Article : Google Scholar : PubMed/NCBI
22	Bose T, Diedrichs-Möhring M and Wildner G: Dry eye disease and uveitis: A closer look at immune mechanisms in animal models of two ocular autoimmune diseases. Autoimmun Rev. 15:1181–1192. 2016. View Article : Google Scholar : PubMed/NCBI
23	Liu NN, Liu L, Li J and Sun YZ: Prevalence of and risk factors for dry eye symptom in mainland china: A systematic review and meta-analysis. J Ophthalmol. 2014:7486542014. View Article : Google Scholar : PubMed/NCBI
24	Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, et al: Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 12:145–151. 2017. View Article : Google Scholar
25	Wang L, Wu X, Shi T and Lu L: Epidermal growth factor (EGF)-induced corneal epithelial wound healing through nuclear factor κB subtype-regulated CCCTC binding factor (CTCF) activation. J Biol Chem. 288:24363–24371. 2013. View Article : Google Scholar : PubMed/NCBI
26	Huo YN, Chen W and Zheng XX: ROS, MAPK/ERK and PKC play distinct roles in EGF-stimulated human corneal cell proliferation and migration. Cell Mol Biol (Noisy-le-grand). 61:6–11. 2015.
27	Nakamura Y, Sotozono C and Kinoshita S: The epidermal growth factor receptor (EGFR): Role in corneal wound healing and homeostasis. Exp Eye Res. 72:511–517. 2001. View Article : Google Scholar : PubMed/NCBI
28	Du H, Hu Z, Bazzoli A and Zhang Y: Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method. PLoS One. 6:e223672011. View Article : Google Scholar : PubMed/NCBI
29	Wilson SE, He YG and Lloyd SA: EGF, EGF receptor, basic FGF, TGF beta-1, and IL-1 alpha mRNA in human corneal epithelial cells and stromal fibroblasts. Invest Ophthalmol Vis Sci. 33:1756–1765. 1992.PubMed/NCBI
30	Kinoshita S, Adachi W, Sotozono C, Nishida K, Yokoi N, Quantock AJ and Okubo K: Characteristics of the human ocular surface epithelium. Prog Retin Eye Res. 20:639–673. 2001. View Article : Google Scholar : PubMed/NCBI
31	Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, et al: TFOS DEWS II pathophysiology report. Ocul Surf. 15:438–510. 2017. View Article : Google Scholar : PubMed/NCBI
32	Ablamowicz AF and Nichols JJ: Ocular surface membrane-associated mucins. Ocul Surf. 14:331–341. 2016. View Article : Google Scholar : PubMed/NCBI
33	Stephens DN and McNamara NA: Altered mucin and glycoprotein expression in dry eye disease. Optom Vis Sc. 92:931–938. 2015. View Article : Google Scholar
34	Xiao X, He H, Lin Z, Luo P, He H, Zhou T, Zhou Y and Liu Z: Therapeutic effects of epidermal growth factor on benzalkonium chloride-induced dry eye in a mouse model. Invest Ophthalmol Vis Sci. 53:191–197. 2012. View Article : Google Scholar
35	Horikawa Y, Shatos MA, Hodges RR, Zoukhri D, Rios JD, Chang EL, Bernardino CR, Rubin PA and Dartt DA: Activation of mitogen-activated protein kinase by cholinergic agonists and EGF in human compared with rat cultured conjunctival goblet cells. Invest Ophthalmol Vis Sci. 44:2535–2544. 2003. View Article : Google Scholar : PubMed/NCBI
36	Wickman G, Julian L and Olson MF: How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death Differ. 19:735–742. 2012. View Article : Google Scholar : PubMed/NCBI
37	Yang L, Sui W, Li Y, Qi X, Wang Y, Zhou Q and Gao H: Substance P inhibits hyperosmotic stress-induced apoptosis in corneal epithelial cells through the mechanism of akt activation and reactive oxygen species scavenging via the neurokinin-1 receptor. PLoS One. 11:e01498652016. View Article : Google Scholar : PubMed/NCBI
38	Mackay M, Williamson I and Hastewell J: (A) Cell biology of epithelia. Adv Drug Deliver Rev. 7:313–338. 1991. View Article : Google Scholar
39	Schrader S, Notara M, Beaconsfield M, Tuft SJ, Daniels JT and Geerling G: Tissue engineering for conjunctival reconstruction: Established methods and future outlooks. Curr Eye Res. 34:913–924. 2009. View Article : Google Scholar : PubMed/NCBI
40	Hori Y, Nishida K, Yamato M, Sugiyama H, Soma T, Inoue T, Maeda N, Okano T and Tano Y: Differential expression of MUC16 in human oral mucosal epithelium and cultivated epithelial sheets. Exp Eye Res. 87:191–196. 2008. View Article : Google Scholar : PubMed/NCBI
41	Yañez-Soto B, Mannis MJ, Schwab IR, Li JY, Leonard BC, Abbott L and Murphy CJ: Interfacial phenomena and the ocular surface. Ocul Surf. 12:178–201. 2014. View Article : Google Scholar : PubMed/NCBI
42	Carser JE and Summers YJ: Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 1:1040–1041. 2006. View Article : Google Scholar
43	Zhang G, Basti S and Jampol LM: Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea. 26:858–860. 2007. View Article : Google Scholar : PubMed/NCBI
44	Lane K and Goldstein SM: Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg. 23:65–66. 2007. View Article : Google Scholar : PubMed/NCBI
45	Methvin AB and Gausas RE: Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg. 23:63–65. 2007. View Article : Google Scholar : PubMed/NCBI
46	Papadopoulos R, Chasapi V and Bachariou A: Trichomegaly induced by erlotinib. Orbit. 27:329–330. 2008. View Article : Google Scholar : PubMed/NCBI
47	Braiteh F, Kurzrock R and Johnson FM: Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 26:3460–3462. 2008. View Article : Google Scholar : PubMed/NCBI
48	Gillani JA, Iqbal M, Nasreen S, Khan A and Samad A: Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib. J Coll Physicians Surg Pak. 18:125–126. 2008.PubMed/NCBI
49	Saif MW and Gnanaraj J: Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutan Ocul Toxicol. 29:62–66. 2010. View Article : Google Scholar
50	Kirkpatrick CA, Almeida DR, Hornick AL, Chin EK and Boldt HC: Erlotinib-associated bilateral anterior uveitis: Resolution with posterior sub-Tenon's triamcinolone without erlotinib cessation. Can J Ophthalmol. 50:e66–e67. 2015. View Article : Google Scholar : PubMed/NCBI
51	Salman A, Cerman E, Seckin D and Kanitez M: Erlotinib induced ectropion following papulopustular rash. J Dermatol Case Rep. 9:46–48. 2015. View Article : Google Scholar : PubMed/NCBI